Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

David Hunter, AAPOS 2021: Dichoptic Digital Therapeutic for Amblyopia

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Apr 19th 2021

It was a pleasure to catch up with Dr David Hunter (Harvard Medical School, Boston, MA, USA) about the dichoptic digital therapeutic for amblyopia.

Questions

  1. What are the greatest challenges of amblyopia therapy, in children? (00:17)
  2. Could you give us a brief overview of the dichoptic digital approaches that are being investigated in amblyopia? (01:17)
  3. Could you tell us a little more about Luminopia One? (02:59)

Speaker Disclosure: David Hunter discloses the following: Advisor and equity holder, Luminopia, Inc. Board member and equity holder, Rebion Inc.

Support: Interview and filming supported by Touch Medical Media Ltd.

Filmed in coverage of AAPOS 2021.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup